Articles
| Open Access |
Vol. 4 No. 03 (2024): Volume 04 Issue 03
| DOI:
https://doi.org/10.37547/medical-fmspj-04-03-01
ENDOSTATIN LEVELS IN PULMONARY ARTERIAL HYPERTENSION: EXPLORING CLINICAL CORRELATIONS
Mohammed Hussein , Physiology and Pharmacology Branch, College of Veterinary Medicine, Al-Qasim Green University, Iraq Arshad Noori Al-Khafaji , Biology Department, Faculty of Sciences, University of Kufa, IraqAbstract
This study investigates the levels of endostatin in patients with pulmonary arterial hypertension (PAH) and explores its potential correlations with various clinical parameters. Endostatin, an endogenous inhibitor of angiogenesis, has been implicated in several cardiovascular conditions, but its role in PAH remains poorly understood. Blood samples were collected from PAH patients, and endostatin levels were measured using [insert method]. Clinical parameters such as [insert parameters] were also assessed. Statistical analysis revealed [insert findings]. Our results suggest a potential link between endostatin levels and specific clinical characteristics in PAH patients, shedding light on its possible involvement in the pathogenesis of this condition.
Keywords
Endostatin, pulmonary arterial hypertension, angiogenesis
References
Allen RP, Schelegle ES, Bennett SH. Diverse forms of pulmonary hypertension remodel the arterial tree to a high shear phenotype. Am J Physiol Heart Circ. Physiol. 2014;307(3):H405-17.
Al-Najeem HT, Al-Dujaili AN. Assessment of Bone Morphogentic protein receptor 2 Level in Pulmonary Arterial Hypertension Disease. Res J Pharm Tech. 2017;10(8):2614-8.
Al-Najeem HT, Al-Dujaili AN. Assessment of Gremlin-1 Level in Pulmonary arterial hypertension disease. Res J Pharm Tech. 2017;10(11):3803-6.
Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013; 8(97):51-9.
Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med. 2001;22(3):385-91.
Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. J Am Coll Cardiol. 2004; 43(12):5S-12S.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25):D34-D41.
Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1): S20-S31.
Toshner M, Tajsic T, Morrell NW. Pulmonary hypertension: advances in pathogenesis and treatment. Br Med Bull. 2010;94(1):21-32.
Eddahibi S, Morrell N, d'Ortho MP, Naeije R, Adnot S. Pathobiology of pulmonary arterial hypertension. Eur Respir J. 2002;20(6): 1559-72.
Ihida-Stansbury K, McKean DM, Lane KB, Loyd JE, Wheeler LA, Morrell NW, et al. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol. Lung Cell. Mol Physiol. 2006;291(4):L694-702.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85.
Article Statistics
Downloads
Copyright License
Copyright (c) 2024 Mohammed Hussein, Arshad Noori Al-Khafaji
This work is licensed under a Creative Commons Attribution 4.0 International License.